Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10849115 | 0.85 | GAA (0.56) | CYP3A4LMNASMN1; SMN2KDM4ESLC6A7 | |
| SCHEMBL390463 | 0.84 | GPR119 (0.57) | GPR119CYP3A4LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL391931 | 0.82 | TRPV1 (0.51) | POLBALDH1A1 | |
| SCHEMBL12964579 | 0.81 | GPR119 (0.77) | GPR119CYP3A4LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL389965 | 0.81 | ALDH1A1 (0.64) | LMNASMN1; SMN2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL386614 | 0.79 | HRH3 (0.51) | LMNASMN1; SMN2HSD17B10SLC6A7ALDH1A1 | |
| SCHEMBL2755876 | 0.79 | CYP3A4 (0.75) | GPR119CYP3A4LMNAHSD17B10KDM4E | |
| SCHEMBL392458 | 0.78 | KDM4E (0.56) | LMNASMN1; SMN2HSD17B10KDM4EPPARG | |
| SCHEMBL387764 | 0.78 | GPR119 (0.58) | GPR119LMNASMN1; SMN2KDM4EHPGD | |
| SCHEMBL390651 | 0.77 | NOS1 (0.49) | LMNASMN1; SMN2HSD17B10KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | claimed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | GRIN1, GRM1, GRIN2C | GPR119 137/4885CYP3A4 2605/4885LMNA 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.